{"filing":{"accession_number":"0001171843-26-006027","cik":"0001801198","ticker":"LEGN","company_name":"Legend Biotech Corp","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"f6k_091426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1801198/000117184326006027/f6k_091426.htm"},"events":[{"id":33134,"run_id":30460,"accession_number":"0001171843-26-006027","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This exhibit presents Legend Biotech's cell therapy pipeline portfolio, detailing the status of multiple programs across autologous, allogeneic, and in vivo therapies targeting oncology and autoimmune indications. The disclosure highlights clinical progress (e.g., CARVYKTI® patient follow-up post-NDA, multiple Phase II/III programs enrolling) and partnerships (Janssen/J\u0026J collaboration, Novartis license agreement), which constitute material operational and strategic updates relevant to investors assessing the company's pipeline value and competitive positioning, though it does not constitute a discrete event like an approval, initiation, or termination.","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36495,"accession_number":"0001171843-26-006027","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit presents Legend Biotech's cell therapy pipeline portfolio, detailing the status of multiple programs across autologous, allogeneic, and in vivo therapies targeting oncology and autoimmune indications. The disclosure highlights clinical progress (e.g., CARVYKTI® patient follow-up post-NDA, multiple Phase II/III programs enrolling) and partnerships (Janssen/J\u0026J collaboration, Novartis license agreement), which constitute material operational and strategic updates relevant to investors assessing the company's pipeline value and competitive positioning, though it does not constitute a discrete event like an approval, initiation, or termination.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:02:41.859160+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36495,"accession_number":"0001171843-26-006027","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit presents Legend Biotech's cell therapy pipeline portfolio, detailing the status of multiple programs across autologous, allogeneic, and in vivo therapies targeting oncology and autoimmune indications. The disclosure highlights clinical progress (e.g., CARVYKTI® patient follow-up post-NDA, multiple Phase II/III programs enrolling) and partnerships (Janssen/J\u0026J collaboration, Novartis license agreement), which constitute material operational and strategic updates relevant to investors assessing the company's pipeline value and competitive positioning, though it does not constitute a discrete event like an approval, initiation, or termination.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:02:41.859160+00:00","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-09-14"}]}